Alon Seri-Levy, Sol-Gel Technologies CEO

Bridge­Bio com­pa­ny sells off rare dis­ease can­di­date to Gal­der­ma part­ner

Is­raeli biotech Sol-Gel Tech­nolo­gies an­nounced Fri­day that it got its hands on a rare dis­ease drug can­di­date from Pelle­Pharm for al­most $75 mil­lion, amid claims that the drug has the po­ten­tial to reach a $300 mil­lion mar­ket.

Ex­ecs said on a con­fer­ence call Fri­day morn­ing that patideg­ib, a hedge­hog sig­nal­ing path­way block­er, is be­ing in­ves­ti­gat­ed to treat Gor­lin syn­drome, a rare ge­net­ic dis­or­der that in­creas­es the risk of de­vel­op­ing cer­tain kinds of can­cer such as basal cell skin can­cer and medul­loblas­toma, a type of brain can­cer. The dis­ease af­fects around one in every 31,000 peo­ple, and an es­ti­mat­ed 70,000 peo­ple world­wide.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.